{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [["autohemotherapy", "gout", "hyperuricemia", "ozone"]], "CitationSubset": [], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "25289033", "DateRevised": {"Year": "2021", "Month": "10", "Day": "21"}, "Article": {"Language": ["eng"], "ArticleDate": [{"Year": "2014", "Month": "09", "Day": "09"}], "ELocationID": [], "Journal": {"ISSN": "1792-0981", "JournalIssue": {"Volume": "8", "Issue": "5", "PubDate": {"Year": "2014", "Month": "Nov"}}, "Title": "Experimental and therapeutic medicine", "ISOAbbreviation": "Exp Ther Med"}, "ArticleTitle": "Efficacy and safety of ozonated autohemotherapy in patients with hyperuricemia and gout: A phase I pilot study.", "Pagination": {"StartPage": "1423", "EndPage": "1427", "MedlinePgn": "1423-1427"}, "Abstract": {"AbstractText": ["Gout is a common form of arthritis; however, there are currently no effective therapies available. Ozonated autohemotherapy (O<sub>3</sub>-AHT) is a controversial, but successful method of treatment for a number of diseases. The present study is the first pilot study investigating the application of O<sub>3</sub>-AHT in patients with hyperuricemia and gout. In total, 10 patients diagnosed with gout were recruited and subjected to O<sub>3</sub>-AHT. Self-reported pain visual analog scale (VAS) scores and creatinine clearance values were evaluated prior to (T0), during (after the fifth session of O<sub>3</sub>-AHT treatment; 1-4 weeks; T1) and following the treatment course (5-28 weeks; T2). At T1, the creatinine clearance rate of the patients significantly increased from 105.14\u00b135.33 (T0) to 121.45\u00b144.52 ml/min (t=2.165, P=0.062), while the pain VAS score decreased from 5.35\u00b12.78 (T0) to 3.30\u00b12.21 (t=2.004, P=0.076). However, at T2, the creatinine clearance rate decreased slightly to 111.15\u00b136.52 ml/min, and no statistically significant difference was observed from the value at T0 (t=1.723, P=0.123). The pain VAS score further decreased to 2.30\u00b12.66 (t=2.628, P=0.027). In conclusion, O<sub>3</sub>-AHT decreased the creatinine clearance rate and the pain VAS scores of patients with hyperuricemia and gout; thus, may be a potential effective therapeutic approach."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pain Therapeutic Center, Xuanwu Hospital, Capital Medical University, Beijing 100053, P.R. China."}], "LastName": "Li", "ForeName": "Lian-Yun", "Initials": "LY"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pain Therapeutic Center, Xuanwu Hospital, Capital Medical University, Beijing 100053, P.R. China."}], "LastName": "Ni", "ForeName": "Jia-Xiang", "Initials": "JX"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Greece", "MedlineTA": "Exp Ther Med", "NlmUniqueID": "101531947", "ISSNLinking": "1792-0981"}}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004;31:1582\u20131587.", "ArticleIdList": ["15290739"]}, {"Citation": "Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med. 2007;120:442\u2013447.", "ArticleIdList": ["17466656"]}, {"Citation": "Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination on Survey III, 1988\u20131994. Am J Kidney Dis. 2002;40:37\u201342.", "ArticleIdList": ["12087559"]}, {"Citation": "Smith E, Hoy D, Cross M, et al. The global burden of gout: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014;73:1470\u20131476.", "ArticleIdList": ["24590182"]}, {"Citation": "Smith EU, D\u00edaz-Torn\u00e9 C, Perez-Ruiz F, March LM. Epidemiology of gout: an update. Best Pract Res Clin Rheumatol. 2010;24:811\u2013827.", "ArticleIdList": ["21665128"]}, {"Citation": "Miao Z, Li C, Chen Y, et al. Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China. J Rheumatol. 2008;35:1859\u20131864.", "ArticleIdList": ["18634142"]}, {"Citation": "Doherty M. New insights into the epidemiology of gout. Rheumatology (Oxford) 2009;48(Suppl 2):ii2\u2013ii8.", "ArticleIdList": ["19447779"]}, {"Citation": "Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol. 2007;3:443\u2013449.", "ArticleIdList": ["17664951"]}, {"Citation": "Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1988;41:778\u2013799.", "ArticleIdList": ["9588729"]}, {"Citation": "Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58:15\u201325.", "ArticleIdList": ["18163481"]}, {"Citation": "Kim SY, De Vera MA, Choi HK. Gout and mortality. Clin Exp Rheumatol. 2008;26(5 Suppl 51):S115\u2013S119.", "ArticleIdList": ["19026153"]}, {"Citation": "Luk AJ, Simkin PA. Epidemiology of hyperuricemia and gout. Am J Manag Care. 2005;11(15 Suppl):S435\u2013S442.", "ArticleIdList": ["16300457"]}, {"Citation": "Arromdee E, Michet CJ, Crowson CS, O\u2019Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatol. 2002;29:2403\u20132406.", "ArticleIdList": ["12415600"]}, {"Citation": "Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58:26\u201335.", "ArticleIdList": ["PMC3266664", "18163497"]}, {"Citation": "Hoskison KT, Wortmann RL. Management of gout in older adults: barriers to optimal control. Drug Aging. 2007;24:21\u201336.", "ArticleIdList": ["17233545"]}, {"Citation": "Cheng HF, Harris RC. Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Curr Pharm Des. 2005;11:1795\u20131804.", "ArticleIdList": ["15892676"]}, {"Citation": "White WB. Cardiovascular risk, hypertension, and NSAIDs. Curr Rheumatol Rep. 2007;9:36\u201343.", "ArticleIdList": ["17437665"]}, {"Citation": "Soleimani M. Dietary fructose, salt absorption and hypertension in metabolic syndrome: towards a new paradigm. Acta Physiol (Oxf) 2011;201:55\u201362.", "ArticleIdList": ["21143427"]}, {"Citation": "Keenan RT, O\u2019Brien WR, Lee KH, et al. Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am J Med. 2011;124:155\u2013163.", "ArticleIdList": ["21295195"]}, {"Citation": "Chernyshev AL, Filimonov RM, Karasev AV, et al. Combined treatment including ozonotherapy of patients with viral hepatitis. Vopr Kurortol Fizioter Lech Fiz Kult. 2008;3:19\u201322. (In Russian)", "ArticleIdList": ["18655281"]}, {"Citation": "De Monte A, van der Zee H, Bocci V. Major ozonated autohemotherapy in chronic limb ischemia with ulcerations. J Altern Complement Med. 2005;11:363\u2013367.", "ArticleIdList": ["15865505"]}, {"Citation": "Bocci V, Borrelli E, Travagli V, Zanardi I. The ozone paradox: ozone is a strong oxidant as well as a medical drug. Med Res Rev. 2009;29:646\u2013682.", "ArticleIdList": ["19260079"]}, {"Citation": "Ripamonti CI, Cislaghi E, Mariani L, Maniezzo M. Efficacy and safety of medical ozone (O(3)) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: Preliminary results of a phase I-II study. Oral Oncol. 2011;47:185\u2013190.", "ArticleIdList": ["21310650"]}, {"Citation": "Zhang W, Doherty M, Pascual E, Bardin T, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) Ann Rheum Dis. 2006;65:1301\u20131311.", "ArticleIdList": ["PMC1798330", "16707533"]}, {"Citation": "Bocci V. Ozone as Janus: this controversial gas can be either toxic or medically useful. Mediators Inflamm. 2004;13:3\u201311.", "ArticleIdList": ["PMC1781533", "15203558"]}, {"Citation": "Bocci V, Valacchi G, Corradeschi F, et al. Studies on the biological effects of ozone: 7. Generation of reactive oxygen species (ROS) after exposure of human blood to ozone. J Biol Regul Homeost Agents. 1998;12:67\u201375.", "ArticleIdList": ["9795834"]}, {"Citation": "Hoffstein S, Weissmann G. Mechanisms of lysosomal enzyme release from leukocytes. IV Interaction of monosodium urate crystals with dogfish and human leukocytes. Arthritis Rheum. 1975;18:153\u2013165.", "ArticleIdList": ["48382"]}, {"Citation": "Kozin F, Ginsberg MH, Skosey JL. Polymorphonuclear leukocyte responses to monosodium urate crystals: modification by adsorbed serum proteins. J Rheumatol. 1979;6:519\u2013526.", "ArticleIdList": ["522099"]}, {"Citation": "Nuki G. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep. 2008;10:218\u2013227.", "ArticleIdList": ["18638431"]}], "ReferenceList": []}], "History": [{"Year": "2014", "Month": "3", "Day": "30"}, {"Year": "2014", "Month": "8", "Day": "4"}, {"Year": "2014", "Month": "10", "Day": "8", "Hour": "6", "Minute": "0"}, {"Year": "2014", "Month": "10", "Day": "8", "Hour": "6", "Minute": "0"}, {"Year": "2014", "Month": "10", "Day": "8", "Hour": "6", "Minute": "1"}, {"Year": "2014", "Month": "9", "Day": "9"}], "PublicationStatus": "ppublish", "ArticleIdList": ["25289033", "PMC4186361", "10.3892/etm.2014.1951", "etm-08-05-1423"]}}], "PubmedBookArticle": []}